|
KMID : 0941819930030010045
|
|
Korean Journal of Clinical Pharmacy
1993 Volume.3 No. 1 p.45 ~ p.53
|
|
|
Clinical Study for Low Dose & Short-Term Therapy of Biphenyl Dimethyl Dicarboxylate(DDB) in the Chronic Hepatitis. Patients with Elevated Serum Aspartate Aminotransferase and Alanine Aminotransferase Levels
|
|
|
|
|
Abstract
|
|
|
|
Biphenyl Dimethyl dicarboxylate(DDB) has been regarded as a safe, effective drug for decreasing serum aminotransferase levels from elevated serum aminotransferase levels, which cause acute or chronic hepatitis and chronic liver diseases. This study was designed to low dose(22.5mg/day) & short-term therapy effectiveness for 4 weeks of DDB in 30 chronic hepatitis patients with elevated serum aminotransferases. The following results were observed. 1. Serum alanine aminotransferase(ALT) levels significantly decresed from 173. 97pm130.62(U/L) of pretreatment level to 32.23pm19.22(U/L) after treatment for 4 weeks(p<0.00l) and normalized patients by 73% 2. Serum aspartate (AST) aminotransferase levels significantly decreased from 94.90pm49.17(U/L) of pretreatment level to 45.30pm23.25(U/L)4 after treatment(p0<0.01). 3. However, no significant effects in the serum AST & ALT changes by which cause hepatitis and hepatitis duration (p>0.05). 4. No significant adverse effects were observed except for mild epigastric discomfort in one patient during DDB treatment It is suggested that DDB small dosage administration can result effectively decreasing serum aminotransferase levels from chronic hepatitis patients with elevated serum aminotransferase levels.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|